London midday: Blue chips power ahead
9th Aug 2010 12:11
Footsie is powering forward on the back of strong performances from financials and miners. Lonmin and Kazakhmys are the best performing miners, while among financials the stand-out stocks are spread around the insurance (Legal & General, Prudential), banking (Barclays), fund management (Schroders )
Read moreLondon open: Footsie rebounds over 5,400
9th Aug 2010 08:48
A late rally in the US on Friday has helped Footsie rebound through 5,400 again. International Power is the best performer on widespread reports it will reveal a merger with French utility GDF Suez. That should trigger a £1.3bn windfall for International Power shareholders. The deal is expected to
Read moreLondon pre-open: Footsie targets 5,400
9th Aug 2010 07:32
A late rally in the US on Friday should be enough to get London back within spitting distance of 5,400. Wall Street added almost 100 points after the FTSE 100 stopped trading for the weekend. Futures prices indicate an early 59-point advance. BP's "static kill" and cementing procedures at the brok
Read moreAstraZeneca pays out $198m over Seroquel
9th Aug 2010 07:09
Drug giant AstraZeneca said it had agreed to pay a total of $198m (£124m) in compensation to about 17,500 claimants in the US in relation to its bipolar disorder treatment Seroquel. The terms of the agreements, which came after court mediation, are confidential, Astra said. Seroquel has been linked
Read moreAstraZeneca Buys 0.5M In Own Shares
2nd Aug 2010 08:43
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN), announced Monday it purchased for cancellation 500,000 ordinary shares at a price of 3253 pence per share. MAIN FACTS: -Shares at 0741 GMT up 4 pence, or 0.12%, at 3242 pence. -By Zechariah Hemans, Dow Jones Newswires; 44-20-7842-9411; zechar
Read moreMARKET TALK: CytoFab Delay Marginal For BTG -Ambrian
30th Jul 2010 09:19
0819 GMT [Dow Jones] A delay to development of BTG's (BGC.LN) experimental sepsis treatment CytoFab has only a marginal impact on BTG's valuation, says Ambrian analyst Chris Redhead. AstraZeneca (AZN.LN), which is developing CytoFab, said Thursday it expects to file the product for approval in 2015
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
30th Jul 2010 09:19
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0819 GMT [Dow Jones] A delay to development of BTG's (BGC.LN) experimental sepsis treatment CytoFab has only a marginal impa
Read moreAstraZeneca Delays BTG's CytoFab To 2015
29th Jul 2010 17:48
LONDON (Dow Jones)--U.K. drug maker AstraZeneca PLC (AZN.LN) Thursday said it will file an experimental sepsis treatment licensed from BTG PLC (BGC.LN) for marketing approval later than previously expected. The Anglo-Swedish drug maker said in a pipeline update released with its second-quarter r
Read moreLondon close: US gloom offsets company cheer
29th Jul 2010 16:33
Footsie closed slightly in the red, despite starting well on the back of well-received company updates, as weakness in the US spread across the Atlantic. AstraZeneca closed sharply higher. The group's potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as
Read moreMARKET TALK: FinnCap Cuts BTG To Hold On CytoFab Delay
29th Jul 2010 15:17
1417 GMT [Dow Jones] FinnCap downgrades BTG PLC (BGC.LN) to hold from buy after AstraZeneca PLC (AZN.LN) puts back development of sepsis treatment CytoFab by a year. AstraZeneca says Thursday it expects to file CytoFab for marketing approval in 2015. It previously said it would be filed in 2014, say
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
29th Jul 2010 15:17
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1417 GMT [Dow Jones] FinnCap downgrades BTG PLC (BGC.LN) to hold from buy after AstraZeneca PLC (AZN.LN) puts back develop
Read moreMARKET TALK: Double Whammy For Eli Lilly
29th Jul 2010 14:40
9:40 (Dow Jones) It was a double-whammy day for drug maker Eli Lilly (LLY) yesterday. First a US appeals court upheld decision overturning patent for LLY cancer drug Gemzar, which means generic competition could begin later this year. Then FDA advisory committee backed AstraZeneca's (AZN) anti-clott
Read moreFTSE 100 movers: Results push market higher
29th Jul 2010 14:30
A raft of good results has boosted Footsie today. Scientific journals and magazines publisher Reed Elsevier says advertising and promotion markets are stabilising as underlying revenues increased 1% in the first half. AstraZeneca's potential blockbuster heart drug Brilinta has received the backi
Read moreLondon afternoon: Footsie off the top
29th Jul 2010 14:28
The Footsie drifted lower over the lunch time session though still remained in positive territory, thanks in large part to enthusiastic responses to results from heavy hitters AstraZeneca, BT and Reed Elsevier. AstraZeneca is sharply higher. The group's potential blockbuster heart drug Brilinta has
Read moreBEFORE THE BELL: US Stock Futures Rise On Strong Earnings Data
29th Jul 2010 13:06
By Polya Lesova Stock futures pointed to opening gains on Wall Street Thursday, as strong earnings reports from European companies buoyed sentiment, with traders awaiting results from oil major Exxon Mobil Corp. and data on U.S. weekly jobless claims. Futures on the Dow Jones Industrial Ave
Read more